Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 

33 protocols found



Protocol No. Title Status
A021502 A021502: Randomized Trial of FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability (ATOMIC*) Open (affiliates only)
ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Open
AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors Open
ALTE15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study Open
APEC1621B NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Open
APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
NRGGI004 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Open
S0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) Open (affiliates only)
S1613 A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification Open (affiliates only)
UW13043 A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of AZD8186 in Patients with Advanced Castration resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB mutated/amplified Advanced Solid Malignancies, as Monotherapy and in Combination with Abiraterone Acetate or AZD2014 Open
UW13044 Loco-regional lymph node staging assessment by gadofosveset trisodium-enhanced FDG18PET/MR in newly diagnosed colon cancer Open
UW13056 Women's Integrative Sexual Health (WISH) Program Research Database Open
UW15054 A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies Open
UW15063 Pembrolizumab in combination with stereotactic body radiotherapy for liver metastatic colorectal cancer Open
UW15106 Genomic analysis of long-term survivors with metastatic cancer Open
UW16009 Treatment of Relapsed or Refractory Neuroblastoma with Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2 Open
UW16029 Feasibility of delivering electronic health record (EHR)-based survivorship care plans and planning to cancer survivors in a community oncology practice Open (affiliates only)
UW16059 Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire Open
UW16107 A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors Open
UW16116 A Phase I/Ib Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Rα)) alone and in combination with PDR001 in Adults with Metastatic Cancers Open
UW16137 An Open-Label, Dose-Finding And Proof Of Concept Study Of The Pd-L1 Probody Therapeutic, Cx-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Anti-Pd-1/Pd-L1 Inhibitor Naïve Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas Open
UW17038 Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) Open
UW17053 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
UW17064 A Phase 2, Multi-center, Open Label Study of NIR-178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma Open
UW17101 UWCCC Rectal and Anal Cancer Registry Open
UW17113 A Study of Nivolumab in Combination With Trametinib With or Without Ipilimumab in Participants With Previously Treated Metastatic Colorectal Cancers Open
UW17120 An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA) Open
UW17147 Pre-Visit Planning in Palliative Care Open
UW17152 An Open-Label Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification Open
UW18004 An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs. Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer Open